MAP2K7 and central nervous system cancer: Selumetinib is a small molecule MEK inhibitor now approved by the United States Food and Drug Administration and European Medicines Agency for the treatment of symptomatic, surgically unresectable plexiform neurofibromas following demonstration of significant efficacy with durable tumor shrinkage in clinical trials [5, 11], and clinical trials investigating the efficacy of selumetinib in treating NF1-associated low-grade gliomas are ongoing [6].